Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

Sean Elliot’s Story

Key Takeaway: The article highlights the commitment to advancing next-generation therapies aimed at improving patient outcomes. It emphasizes the importance of patient stories and clinical trials in the development process. Additionally, it provides insights into the company's leadership and governance structure.
Price reaction · baseline $2.89 (2024-08-01 close) · hit after-hours · clean, no other ELDN news in the window
day 0 close · peak
-4.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Advancement of next-generation therapies.
  • Focus on achieving better patient outcomes.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

We’re advancing next generation therapies to achieve better outcomes for patients.
See video here on Vimeo
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What is the focus of ELDN?

ELDN focuses on advancing next-generation therapies for improved patient outcomes.

How does ELDN support clinical trials?

The company emphasizes the importance of patient stories and clinical trials in its development process.

Last updated: Aug 1, 2024